Muniyandi Malaisamy, Chelvanayagam Karthick, Salam Sahil Abdul, Vadamalai Sathishkumar, Rajsekar Kavitha, Ramachandran Rajeswari
ICMR-National Institute for Research in Tuberculosis, Chennai, India.
ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Epilepsy Res. 2025 Feb;210:107510. doi: 10.1016/j.eplepsyres.2025.107510. Epub 2025 Jan 9.
Epilepsy is a major neurological disorder, typically managed with Anti-Seizure Medication (ASM). Nevertheless, a substantial 30 % of patients did not respond satisfactorily to ASMs, classifying their condition as Drug-Resistant Epilepsy (DRE). Vagus Nerve Stimulation (VNS) was recommended as a potential solution.
To evaluate clinical efficacy of VNS on patients with DRE in reduction of seizures through a systematic review and meta-analysis using a random effects model.
A systematic search was done from PubMed, ScienceDirect, Cochrane Library and Google Scholar databases on observational studies and randomized controlled trials (RCTs) for the clinical effectiveness of VNS among DRE patients. A meta-analysis was performed to obtain the pooled estimate of the clinical effectiveness of VNS in terms of seizure reduction and the odds ratio (OR) for patients achieving > 50 % seizure reduction. Heterogeneity was assessed using visual inspection of forest plots and I statistic.
A total of 1023 articles were retrieved from the electronic search. After removing duplicates, non-relevance and non-availability of efficacy data, 28 articles were included in the final analysis. Of these, 9 are RCTs and 19 are observational studies. The pooled estimate of > 50 % seizure reduction was 0.46 (95 % CI: 0.40-0.51) and the pooled estimate of the OR comparing > 50 % vs ≤ 50 % seizure reduction was 0.76 (95 % CI: 0.44-1.29).
Our meta-analysis showed that 46 % of DRE patients have experienced ≥ 50 % seizure reduction with VNS treatment. It should be considered in patients in whom ASM has failed or who continue to experience seizures after medication.
癫痫是一种主要的神经系统疾病,通常采用抗癫痫药物(ASM)进行治疗。然而,仍有相当比例(30%)的患者对ASM反应不佳,其病情被归类为药物难治性癫痫(DRE)。迷走神经刺激(VNS)被推荐为一种潜在的解决方案。
通过使用随机效应模型的系统评价和荟萃分析,评估VNS对DRE患者减少癫痫发作的临床疗效。
在PubMed、ScienceDirect、Cochrane图书馆和谷歌学术数据库中进行系统检索,查找关于VNS在DRE患者中临床有效性的观察性研究和随机对照试验(RCT)。进行荟萃分析以获得VNS在减少癫痫发作方面临床有效性的合并估计值,以及癫痫发作减少>50%的患者的优势比(OR)。使用森林图的视觉检查和I统计量评估异质性。
通过电子检索共检索到1023篇文章。在去除重复、不相关和无疗效数据的文章后,最终分析纳入了28篇文章。其中,9篇是RCT,19篇是观察性研究。癫痫发作减少>50%的合并估计值为0.46(95%CI:0.40-0.51),比较癫痫发作减少>50%与≤50%的OR合并估计值为0.76(95%CI:0.44-1.29)。
我们的荟萃分析表明,46%的DRE患者接受VNS治疗后癫痫发作减少≥50%。对于ASM治疗失败或用药后仍有癫痫发作的患者,应考虑使用VNS。